Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

This this study is for individuals who have treatment-naïve extensive-stage small cell lung cancer (small cell lung cancer that wont respond to treatment). Doctors leading this study hope to learn if combining durvalumab, carboplatin and etoposide with hyofractionated ablative radiation therapy (radiation focused on certain parts of the body) will help treat your cancer and improve how long you can live with extensive-stage small cell cancer without it getting worse (progression-free survival). Your participation in this research will last about 48 months. Durvalumab along with chemotherapy h

Trial Details

NCT ID
NCT05068232
Phase
PHASE2
Sponsor
University of Chicago
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Ablative Radiation
  • Durvalumab
  • Etoposide
  • Carboplatin
Locations (sample)
  • Chicago, Illinois, United States|41.85003,-87.65005
  • Madison, Wisconsin, United States|43.07305,-89.40123

Key Eligibility Criteria

  • For inclusion in the study patients must fulfill all of the following criteria:
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF…
  • Age \> 18 years at time of study entry.
  • Have a histologic/clinically confirmed diagnosis of small cell lung cancer with known metastatic disease.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →